Teva Pharmaceutical Industries Limited (NYSE:TEVA) Short Interest Update

Teva Pharmaceutical Industries Limited (NYSE:TEVA) saw a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 22,360,000 shares, a growth of 41.5% from the January 15th total of 15,800,000 shares. Based on an average daily trading volume, of 11,370,000 shares, the short-interest ratio is currently 2.0 days.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares in the company, valued at approximately $15,296,950. This represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Christine Fox sold 19,388 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. This trade represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

A number of hedge funds have recently bought and sold shares of the stock. Stifel Financial Corp raised its position in shares of Teva Pharmaceutical Industries by 54.0% during the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after buying an additional 23,283 shares during the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in Teva Pharmaceutical Industries by 7.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after acquiring an additional 33,277 shares in the last quarter. Thrivent Financial for Lutherans lifted its position in shares of Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock worth $4,046,000 after acquiring an additional 40,218 shares during the period. Sio Capital Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $24,314,000. Finally, CWA Asset Management Group LLC bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $3,340,000. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA traded down $0.40 during mid-day trading on Friday, hitting $16.24. 12,463,268 shares of the company’s stock traded hands, compared to its average volume of 13,828,842. The firm has a market capitalization of $18.39 billion, a price-to-earnings ratio of -11.20, a price-to-earnings-growth ratio of 1.39 and a beta of 0.71. The firm has a 50 day moving average of $19.96 and a two-hundred day moving average of $18.51. The company has a current ratio of 0.98, a quick ratio of 0.61 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 12 month low of $12.51 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, equities analysts forecast that Teva Pharmaceutical Industries will post 2.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on TEVA. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. Barclays decreased their price target on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research note on Thursday, January 30th. UBS Group lowered their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. StockNews.com lowered Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Finally, JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and a consensus target price of $23.57.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.